Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Heath Lukatch

AddedMar 31, 2024

UpdatedMay 31, 2026

Heath Lukatch

Heath Lukatch

Founder, Red Tree Venture Capital.

Crunchbase LinkedIn

Heath Lukatch's Career

Red Tree Venture Capital.

Red Tree Venture Capital.

Portola, CA, US

Founder

SightLine Partners

SightLine Partners

Bloomington, MN, US

Co-Founder

AnaptysBio

San Diego, CA, US

Board Member· Board

Inogen

Goleta, CA, US

Board Member· Board

Acrigen Biosciences

Acrigen Biosciences

Alameda, CA, US

Board Member· Board

ViewPoint Therapeutics

ViewPoint Therapeutics

San Francisco, CA, US

Board Member· Board

Adynxx

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Heath Lukatch's Career

Red Tree Venture Capital.

Red Tree Venture Capital.

Investment FirmInvestment Firm72020Portola, CA, US

Founder

Similar to Red Tree Venture Capital.

PTV Healthcare CapitalAustin, TX, USest. 2003PTV Healthcare CapitalAustin, TX, US · est. 2003

PTV Sciences LP: A global venture capital firm investing in healthcare and life sciences.

Investment Firm10

Emergent Venturesest. 2020Emergent Venturesest. 2020

Tech-focused investment fund leveraging data, analytics, & AI to unlock value.

Investment Firm2

Red Shepherd VenturesLos Gatos, CA, USest. 2021Red Shepherd VenturesLos Gatos, CA, US · est. 2021

Red Shepherd Ventures: Early-stage investment firm leveraging a world-class GTM network, based in California.

Investment Firm2

Treehouse Global VenturesChicago, IL, USest. 2018Treehouse Global VenturesChicago, IL, US · est. 2018

Treehouse Global Ventures: A women-led fund investing in and nurturing female and minority cannabis businesses.

Investment Firm5

SightLine Partners

SightLine Partners

Investment FirmInvestment Firm82004Bloomington, MN, US

Co-Founder

Leadership at SightLine Partners

Rob ShurtleffCo-Founder

Charles J. 'Chuck' LicariBoard Member

Similar to SightLine Partners

VisionTech PartnersIndianapolis, IN, USest. 2009VisionTech PartnersIndianapolis, IN, US · est. 2009

VisionTech Partners LLC: A US-based tech investment firm, funding ventures in IT, agriculture, and manufacturing.

Investment Firm30

Visionary Venture FundAliso Viejo, CA, USest. 2016Visionary Venture FundAliso Viejo, CA, US · est. 2016

Visionary Venture Fund LLC: A venture capital firm investing in emerging ophthalmology companies.

Investment Firm9

ExSight VenturesNew York City, NY, USest. 2014ExSight VenturesNew York City, NY, US · est. 2014

ExSight Ventures: A venture capital firm funding early-stage ophthalmic solutions in biotech, medical devices, and software.

Investment Firm8

Skyline VenturesPalo Alto, CA, USest. 1997Skyline VenturesPalo Alto, CA, US · est. 1997

Skyline Venture Management LLC: A US-based venture capital firm specializing in life science and medical sectors.

Investment Firm12

AnaptysBio

Public$85.9M962005San Diego, CA, US

Board Member· Board

Leadership at AnaptysBio

Dennis FentonBoard Member

John OrwinBoard Member

Jamie TopperBoard Member

J. Anthony WareBoard Member

Andrea CubittCo-Founder

Hollings RentonBoard Member

Similar to AnaptysBio

NantkwestCulver City, CA, USCancer Treatment, Immunotherapyest. 2014NantkwestCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51

INmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17

Santa Ana BioAlameda, CA, USBiologics, Therapiesest. 2021Santa Ana BioAlameda, CA, US · est. 2021

Santa Ana Bio designs precision biologics using deep cell profiling tech, specializing in autoimmune diseases.

Series A · $35.3M18

Anthera PharmaceuticalsHayward, CA, USPharmaceuticalsest. 2004Anthera PharmaceuticalsHayward, CA, US · est. 2004

Anthera Pharmaceuticals: A US biopharma firm specializing in inflammation and autoimmune disease treatments.

Public · $101.5M21

Inogen

Public$73.3M1k2001Goleta, CA, US

Board Member· Board

Leadership at Inogen

Raymond HuggenbergerBoard Member

Ali BauerleinCo-Founder

Christine M KingBoard Member

Steve CooperBoard Member

Scott A BeardsleyBoard Member

Byron MyersBoard Member

Similar to Inogen

Invent MedicalCarlsbad, CA, USMedical Devicesest. 2014Invent MedicalCarlsbad, CA, US · est. 2014

Invent Respiratory: Developing advanced respiratory care devices for patient recovery and rehabilitation.

Seed · $258.1k6

PulmonxRedwood City, CA, USMedical Devicesest. 1998PulmonxRedwood City, CA, US · est. 1998

Pulmonx Corp., based in Redwood City, US, globally develops and markets medical devices for pulmonary disorders.

Public · $276.9M269

Rapid OxygenStamford, CT, USMedical Devicesest. 2016Rapid OxygenStamford, CT, US · est. 2016

Rapid Oxygen: Medtech firm offering FDA-cleared, portable, non-explosive oxygen devices for emergencies.

Series A · $5.5M75

AeronicsPittsburgh, PA, USOxygen Therapyest. 2017AeronicsPittsburgh, PA, US · est. 2017

Aeronics: Innovating portable oxygen therapy with cutting-edge technology.

Acrigen Biosciences

Acrigen Biosciences

Pre-Seed$1.2M112019Alameda, CA, US

Board Member· Board

Leadership at Acrigen Biosciences

David RabukaCo-Founder

Joe Bondy-DenomyCo-Founder

Similar to Acrigen Biosciences

Editas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

MetagenomiEmeryville, CA, USGene Editingest. 2016MetagenomiEmeryville, CA, US · est. 2016

Metagenomi: Pioneering next-gen gene-editing systems to treat genetic diseases.

Series B · $457M191

Amber BioSan Francisco, CA, USGene Editingest. 2021Amber BioSan Francisco, CA, US · est. 2021

Amber Bio, a San Francisco-based biotech firm, pioneers gene editing to reach untapped patient groups.

GenEditSouth San Francisco, CA, USTherapeutic Deliveryest. 2016GenEditSouth San Francisco, CA, US · est. 2016

GenEdit Inc., a biotech firm in California, innovates CRISPR-based therapeutic delivery systems.

Series A · $67.7M47

ViewPoint Therapeutics

ViewPoint Therapeutics

Acquired$39M02014San Francisco, CA, US

Board Member· Board

Leadership at ViewPoint Therapeutics

Ed HurwitzBoard Member

Jason GestwickiCo-Founder

Leah MakleyCo-Founder

Adynxx

Series B$23.5M62007San Francisco, CA, US

Board Member· Board

Leadership at Adynxx

Julien MametBoard Member

Pierre LegaultBoard Member

Stan AbelBoard Member

Dennis PodlesakBoard Member

Eckard WeberBoard Member

Greg FlesherBoard Member

Heath Lukatch's Similar Executives & Operators

Lau Eng BoonBoard Member · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Achmad ZakyCo-Founder · Bukalapak

Nugroho HerucahyonoCo-Founder · Bukalapak

Chi-hyung SongBoard Member · Dunamu

Haeil YiCo-Founder · Dunamu

Hyoung-nyon KimCo-Founder · Dunamu

People Similar to Heath Lukatch

Elizabeth MoraBoard Member · MKS

Heather RiderBoard Member · Inogen

John RiceCo-Founder · Triathlon Medical Venture Partners